SCHEMBL12038337

SCHEMBL12038337

CC(=O)Oc1c(Cl)cc2c(C)c(C(=O)ON3C(=O)CCC3=O)c(=O)oc2c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.36
▸ GLA P06280 10/20 0.36
▸ GAA P10253 10/20 0.36
▸ ALDH1A1 P00352 9/20 0.36
▸ HPGD P15428 8/20 0.36
▸ HIF1A Q16665 4/20 0.36
▸ CASP1 P29466 4/20 0.36
▸ CASP7 P55210 4/20 0.36
▸ HSD17B10 Q99714 4/20 0.36
▸ MAPT P10636 3/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ GFER P55789 2/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ GBA1 P04062 1/20 0.34
▸ POLB P06746 1/20 0.31
▸ HTT P42858 2/20 0.31
▸ ERAP1 Q9NZ08 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12038339 0.88 KDM4E (0.36) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12038356 0.78 LMNA (0.33) KDM4EGLAGAAALDH1A1CASP1
SCHEMBL12038371 0.76 LMNA (0.32) KDM4EGLAGAAALDH1A1CASP1
SCHEMBL12038319 0.72 KDM4E (0.54) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12038411 0.70 PSMB8 (0.32) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12038352 0.69 LMNA (0.33) KDM4EGLAGAAALDH1A1CASP1
SCHEMBL12038297 0.68 MAOB (0.39) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12038362 0.68 MAOB (0.34) MAPTMEN1KMT2A
SCHEMBL12038331 0.68 TMIGD3 (0.38) DRD2DRD1
SCHEMBL12038288 0.65 KDM4E (0.49) KDM4EGLAGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES CYP3A7, XPO7, HCCS KDM4E 4529/4885GLA 649/4885GAA 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback